Clinical trial
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory…
NCT00474929 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00474929 |
|---|---|
| Title | Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma |
| Official title | A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | University of Iowa |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | RAD001, Sorafenib |
| Enrollment | 103 |
| Start date | Aug 29, 2007 |
| Primary completion | Nov 5, 2011 |
| Completion | Aug 8, 2019 |
| First posted | May 17, 2007 |
| Last update posted | Aug 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: